AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02853227 — intervention group
Intervention type: OTHER
Intervention: digital photography
Description: Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
Study NCT04073303 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Day 1 Administration of bilateral intramuscular injections into the masseter
Study NCT02533674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus PM060184
Study NCT04778709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puros allograft
Description: Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone.
Study NCT04778709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puros allograft
Description: Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone.
Study NCT04315207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter.
Study NCT02178436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04315207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person meeting
Description: All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter.
Study NCT01579305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® Volbella with Lidocaine
Description: Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
Study NCT02178436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Given IV
Study NCT01579305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane-L®
Description: Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
Study NCT01894360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 200 mg/mL
Description: Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
Study NCT04341350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol + analgesic drug
Description: sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
Study NCT01820104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole, 30 mg per day for 6 days
Study NCT04341350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane + analgesic drug
Description: sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
Study NCT03911193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
Study NCT01377311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant of cultured limbal stem cells on cornea
Description: Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
Study NCT03203707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Description: The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
Study NCT00576394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Insulin drip
Description: IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
Study NCT00576394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin drip to keep serum glucose between 80-120mg/dl.
Study NCT00553111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational video
Description: educational video
Study NCT00732459 — intervention group
Intervention type: DEVICE
Intervention: Electro-acupuncture preconditioning
Description: electro-acupuncture
Study NCT03391154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxin
Description: 90 female received levothroxine
Study NCT01835561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Single oral dose of 4-mg capsule
Study NCT01835561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4-mg capsule
Study NCT01686204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat dairy yogurt
Description: Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
Study NCT01686204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat dairy yogurt
Description: Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
Study NCT01686204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy pudding
Description: Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
Study NCT04334681 — intervention group
Intervention type: PROCEDURE
Intervention: Un-roofing curettage method
Description: In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
Study NCT04334681 — intervention group
Intervention type: PROCEDURE
Intervention: Modified Limberg Flap Group
Description: In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
Study NCT03882372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow
Description: See arm description.
Study NCT01033370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clevidipine.
Description: Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
Study NCT01229111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given PO
Study NCT01229111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01229111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01229111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01686204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy pudding
Description: Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
Study NCT01815437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom Vitamin D2
Description: 2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
Study NCT03623490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: managment of oral therapy
Description: Initial consultation with a trio oncologist / pharmacist / nurse
Study NCT01210599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
Study NCT01749293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Transplant
Description: Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
Study NCT01749293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
Study NCT01749293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
Study NCT01749293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
Study NCT01749293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
Study NCT02250573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study NCT04370847 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
Study NCT04370847 — intervention group
Intervention type: DRUG
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT01815437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 2000 IU crystalline cholecalciferol once/day for 12 weeks
Study NCT04370847 — intervention group
Intervention type: DRUG
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study NCT04370847 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision
Study NCT03292042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical health promotion program
Description: The program has 24 sessions. Each session has two parts:~* first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~* Second part: 1 hour of physical activity (walk)
Study NCT02380521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (BYDUREON™)
Description: Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg
Study NCT04370847 — intervention group
Intervention type: RADIATION
Intervention: lung ultrasound scans
Description: lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
Study NCT01815437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2 - Ergocalciferol
Description: 2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
Study NCT01815437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mushroom Extract
Description: Same quantity of mushroom extract in a capsule
Study NCT04370847 — intervention group
Intervention type: OTHER
Intervention: Ultrasound Assessment of the Inferior Vena Cava
Description: The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
Study NCT04958564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCP
Description: 1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load.
Study NCT04370847 — intervention group
Intervention type: OTHER
Intervention: Optic nerve sheath diameter
Description: Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
Study NCT04370847 — intervention group
Intervention type: DRUG
Intervention: ringer acetate
Description: 1000 ml ringer acetate will be administered over 2 hours.
Study NCT04370847 — intervention group
Intervention type: DRUG
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
Study NCT04370847 — intervention group
Intervention type: DRUG
Intervention: Intravenous Syntocinon
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
Study NCT02893254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI303
Description: 12 cycles. IBI303: 40 mg, iH
Study NCT03641677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centralized Lung Evaluation System
Description: Assessment of allograft lung for transplant suitability
Study NCT03641677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Transplant
Description: Orthotopic single or double lung transplantation.
Study NCT03641677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Transplant
Description: Orthotopic single or double lung transplantation.
Study NCT04346238 — intervention group
Intervention type: OTHER
Intervention: Reuse of existing data from patients' medical records
Description: Reuse of existing data from patients' medical records
Study NCT02217007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-102 sustained release tablet
Description: SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
Study NCT03555045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conducting the slanted recession technique on the superior and inferior poles
Description: conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
Study NCT03555045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conducting the augmented recession technique on the muscle
Description: conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
Study NCT02893254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 12 cycles. Adalimumab: 40mg, iH
Study NCT03224637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
Study NCT01450267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Reduced Glutathione
Description: 10 mg/kg, twice daily, 12 months
Study NCT01450267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological solution
Description: 0,13 ml/kg body weight, twice daily, 12 months
Study NCT05954663 — intervention group
Intervention type: OTHER
Intervention: Basic demographic information
Description: Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation
Study NCT00744419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
Study NCT04534621 — intervention group
Intervention type: OTHER
Intervention: Electronic survey
Description: Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
Study NCT05891522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: portable scanner
Description: performing a portable cranial scanner on cerebro-injured intensive care patients
Study NCT05891522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixed scanner
Description: performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
Study NCT03224637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (conventional)
Study NCT00004931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00004931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02697682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection with the stromal vascular fraction (SVF) of adipose tissue
Description: Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
Study NCT03811145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tendoncel
Description: Platelet lysate gel
Study NCT03811145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control gel
Description: Placebo control gel